Ceftobiprole medocaril (Zevtera) – FDA approved antibiotic for three infections including methicillin-resistant Staphylococcus aureus

Jyoti Singh

doi:10.62110/sciencein.jmc.2024.692

Ceftobiprole medocaril (Zevtera) – FDA approved antibiotic for three infections including methicillin-resistant Staphylococcus aureus

Authors

Jyoti Singh M.D. University

DOI:

https://doi.org/10.62110/sciencein.jmc.2024.692

Keywords:

Drug Resistance, Antibiotics, Heterocyclic drugs, MRSA, Zevtera, antibacterial drug resistance, Basilea, beta-lactam

Abstract

The U.S. Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection) for multiple therapeutic indications. Zevtera (a product of Basilea company) is now authorized for use in adults to treat Staphylococcus aureus bloodstream infections (bacteremia), including cases of right-sided infective endocarditis. Additionally, it is approved for adults with acute bacterial skin and skin structure infections (ABSSSI). Further, Zevtera is also approved for treating community-acquired bacterial pneumonia (CABP) in pediatric patients aged three months to less than 18 years. This broad-spectrum antibiotic offers a significant advancement in managing severe bacterial infections across different age groups, enhancing treatment options for both healthcare providers and patients.

URN:NBN:sciencein.jmc.2024.692

Author Biography

Jyoti Singh, M.D. University

Botany, Hindu Girls College, Sonepat

Downloads

Article PDF

Published

2024-04-12

Issue

Vol. 4 No. 2 (2024)

Section

Medicinal Chemistry

URN

https://scholar.google.com/scholar?q=urn:nbn:sciencein.jmc.2024.692

License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

(1)

Singh, J. Ceftobiprole Medocaril (Zevtera) – FDA Approved Antibiotic for Three Infections Including Methicillin-Resistant Staphylococcus Aureus. J. Mol. Chem. 2024, 4 (2), 692. https://doi.org/10.62110/sciencein.jmc.2024.692.